Macquarie Group
ACRS icon

Macquarie Group’s Aclaris Therapeutics ACRS Stock Holding History

Macquarie Group’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-3,497
Closed -$3.85K – 1656
2024
Q2 		$3.85K Buy
+3,497
New +$4.11K ﹤0.01% 1744
2022
Q4 		– Sell
-1,568
Closed -$25K – 1744
2022
Q3 		$25K Hold
1,568
– – ﹤0.01% 2137
2022
Q2 		$22K Hold
1,568
– – ﹤0.01% 2271
2022
Q1 		$27 Hold
1,568
– – ﹤0.01% 2316
2021
Q4 		$23K Hold
1,568
– – ﹤0.01% 2361
2021
Q3 		$28K Buy
+1,568
New +$25.1K ﹤0.01% 2378

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Macquarie Group's ACRS Position: Q3 2024 in Review

Macquarie Group sold out of Aclaris Therapeutics (ACRS) in Q3 2024, closing a stake of 3,497 shares — an estimated $3.85K sold.

Macquarie Group first reported a position in ACRS in Q3 2021 and held it in 6 quarters. The position peaked at $28K in Q3 2021. 81 funds tracked by Wall St. Rank hold ACRS as of Q3 2024.

  • Macquarie Group reported no remaining Aclaris Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Macquarie Group sold 3,497 Aclaris Therapeutics shares in Q3 2024, an estimated $3.85K.
  • Macquarie Group first reported a position in Aclaris Therapeutics in Q3 2021 and held it in 6 quarters.
  • Macquarie Group's Aclaris Therapeutics position peaked at $28K in Q3 2021.
  • 81 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2024.

Based on Macquarie Group's 13F filing for Q3 2024, filed 14 Nov 2024.